November 16, 2026

Grey Matters Announces Accreditation for its Flagship NovaScan Neuroimaging Clinics™ Location in Florida and Completes Medicare and Medicaid Enrollment

VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce that its flagship NovaScan Neuroimaging Clinics™ location in Davie, Florida has received accreditation and has completed its full enrollment in both U.S. based Medicare and Medicaid programs.

All diagnostic imaging centers in the U.S must be accredited by one of four governing bodies to fully enroll with, and to be paid by Medicare, and to negotiate “in-network” contracts with most private insurers. This is a major commercial milestone for the Company because the services of its NovaScan Neuroimaging Clinics™ Davie location will now be accessible to all eligible Americans enrolled in Medicare and Medicaid, with established billing codes for both the brain PET scans the clinic will conduct along with the relevant isotopes utilized in the diagnostic imaging procedure.

The inaugural NovaScan Neuroimaging Clinics™ location is at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital, and is the first of its kind in the U.S. to provide brain dedicated PET scans to aid in the detection of Alzheimer’s Disease (AD) and other forms of neurodegenerative disease.




HCA Florida University Medical Office Building / Davie, Florida

Accreditation demonstrates to patients and regulators that a new center meets rigorous clinical standards including:

- **Radiation Dose Control:** Accrediting bodies review scanning protocols and imaging equipment calibration to ensure patients are not exposed to excessive or unnecessary radiation.
- **Diagnostic Accuracy:** Reviewers evaluate actual sample clinical images from the center's imaging equipment to verify they are detailed enough to prevent misdiagnoses or repeat scans.
- **Staff Qualifications:** The process verifies that the interpreting radiologists, medical physicists, and performing technologists hold valid licensing, certifications, and engage in ongoing training.

In summary, accreditation serves as an industry attested validation to referring doctors that an outside imaging center will produce quality images and reliable scan reports, employ qualified staff, and follow proper safety protocols for their patients.

NovaScan Neuroimaging Clinics™ locations will feature the U.S. FDA-cleared CareMiBrain™ system. This is a ground-breaking, new dedicated brain PET scanner with a comfortable chair styled design, that does not require an integrated Computed Tomography (CT) component to produce high-quality images, resulting in 25% less radiation exposure for patients. Brain PET scans for beta-amyloid plaque detection associated with advancing Alzheimer's (AD) are covered by Medicare, Medicaid, and most private insurance for patients 65+.



The CareMiBrain™ PET Brain Scanning System

“We have now reached the point in our commercialization pathway where we can begin introducing doctors and patients to the many features of our new clinic, including our brain dedicated PET scan technology,” said Christopher J. Moreau, CEO of Grey Matters Health Inc. “Advanced image resolution and clarity for earlier diagnosis of neuro-degenerative diseases, and an enhanced patient experience with high-touch hospitality at our clinics, is the professional care and service message we will be delivering as we work to establish a chain of dedicated brain PET imaging clinics across the U.S.”

For more information please contact:

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

cjmoreau@greymatters-health.com
info@greymatters-health.com
www.greymatters-health.com

About Grey Matters

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S.

for the earlier detection of Alzheimer's Disease and other forms of neurodegenerative disease.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include, the successful negotiation of payor contracts, the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/9e516280-e1ea-41e5-ab52-53373ca96fe0

https://www.globenewswire.com/NewsRoom/AttachmentNg/2a624c6f-afdc-4941-baa1-21f0c0ce6385

This press release was published by a CLEAR® Verified individual.

Grey Matters Health

Source: Grey Matters Health Inc.

HCA Florida University Medical Office Building / Davie, Florida



HCA Florida University Medical Office Building / Davie, Florida

The CareMiBrain™ PET Brain Scanning System



The CareMiBrain™ PET Brain Scanning System